Send feedback

BRCA1 p.Val11Gly

c.32T>G · rs80357017 · VCV245973

Likely pathogenic Expert panel
Classification
Likely pathogenic
ClinVar
Review
Expert panel ★★★☆
ClinVar · 6 submitters
AlphaMissense
likely pathogenic
0.7047 · ACMG-weighted
gnomAD v4.1
Absent
absent from gnomAD v4.1
Missense predictors
3/3 damaging
AlphaMissense, REVEL, SaProt
Conditions
3
BRCA1-related cancer predisposition

ClinGen expert panel — ENIGMA BRCA1 and BRCA2 VCEP

Likely Pathogenic for BRCA1-related cancer predisposition. Applied ACMG criteria (verbatim):

PM2_Supporting PS3 PP3

Curation rationale (ClinGen, verbatim)

The c.32T>G variant in BRCA1 is a missense variant predicted to cause substitution of Valine by Glycine at amino acid 11 (p.(Val11Gly)). This variant is absent from gnomAD v2.1 (exomes only, non-cancer subset, read depth ≥25) and gnomAD v3.1 (non-cancer subset, read depth ≥25) (PM2_Supporting met). Reported by 2 calibrated studies to exhibit protein function similar to pathogenic control variants (PMIDs: 30209399, 35659930) (PS3 met). This BRCA1 missense variant is within a key functional domain and the computational predictor BayesDel (noAF) gives a score of 0.325, above the recommended threshold of 0.28 for prediction of impact on BRCA1 function via protein change. A SpliceAI score of 0.05 predicts no impact on splicing (score threshold ≤0.1) (PP3 met). Multifactorial likelihood ratio analysis using clinically calibrated data produced a combined LR for this variant of 1.15 (based on Family History LR=1.15), which is above the ENIGMA BRCA1/2 VCEP threshold for BP5 (>0.48) and below PP4 (<2.08) (BP5 and PP4 not met; PMID: 31853058). In summary, this variant meets the criteria to be classified as a Likely pathogenic variant for BRCA1-related cancer predisposition based on the ACMG/AMP criteria applied as specified by the ENIGMA BRCA1/2 VCEP (PM2_Supporting, PS3, PP3).

ClinGen Evidence Repository → · reported verbatim, not re-tallied by Sugi Variant.

Computational evidence

Protein change
AlphaMissense0.7047likely pathogenic ✓ concordant with ClinVar · top 6% in BRCA1
REVEL0.753pathogenic-leaning
SaProtLLR -10.82damaging
⇒ AlphaMissense, REVEL and SaProt all call this damaging.
Splicing
SpliceAI—not assessed · no allele here is in the release
Constraint at this position
ConservationphyloP 11phastCons 1
Regional constrainto/e 0.91unconstrained · MANE · 78 kb · p 4.8e-05 · regional, not allelic
Overall
CADD25.7PHRED · no single calibrated threshold — expert panels disagree

AlphaMissense carries the ACMG weight for missense; REVEL and SaProt are independent agreement signals.

Population frequency

gnomAD v4.1 · exomes + genomes

Absent from gnomAD v4.1. Not observed in any sequenced alleles — a rarity signal (ACMG PM2-supporting), not evidence of pathogenicity on its own.

Variant & gene context

Gene
BRCA1
Protein
p.Val11Gly
Coding
c.32T>G
MANE Select
NM_007294
dbSNP
rs80357017
Type
single nucleotide variant
Location
chr17:43124065 (GRCh38)
Gene constraint
LOEUF 0.885 · pLI <0.01 · ClinGen HI 3/3 (gnomAD)
Structure
AlphaFold pLDDT 41.99 · 33 PDB
Residue 11
an α-helix; a UniProt-annotated variant site (found in breast-ovarian cancer patients; uncertain significance)
Full BRCA1 gene report on Sugi Atlas → Gene function, pathways, protein structure, interactions & more

Similar variants

Built on 18 open, versioned datasets — ClinVar, gnomAD, AlphaMissense, REVEL, ClinGen & more — plus Sugi Variant's own cross-source analysis. Source data 2026-01–2026-10, ClinVar 2026-10. Full sources & versions →

Cite Sugi Variant

Gür T. Sugi Variant: A Deterministic Per-Variant Germline Reference from a Knowledge Graph for Humans and AI Agents. 2026. doi:10.5281/zenodo.21509445. This variant: https://sugi.bio/variant/brca1-p-val11gly (accessed [today's date]).

Preprint & method: sugi.bio/variant/method Machine-readable: this page as Markdown